Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beach

Showing results (301-310 of 320) with videos related to

Pageof 32
Sort By:
Anesthesia and Analgesia|April 3, 2012
Multiple reservoirs contribute to intraoperative bacterial transmissionRandy W Loftus, Jeremiah R Brown, Matthew D Koff, et al.
Leukemia|October 3, 2018
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Anna Dolnik, Lin Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Journal of Hematology & Oncology|August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialFarhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
BMC Cancer|December 16, 2017
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimensJohn F Seymour, Hartmut Döhner, Aleksandra Butrym, et al.
Haematologica|September 23, 2021
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trialGail J Roboz, Hartmut Döhner, Christopher Pocock, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Blood|May 20, 2015
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsHervé Dombret, John F Seymour, Aleksandra Butrym, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJohn Koreth, Joseph Pidala, Waleska S Perez, et al.
International Journal of Molecular Sciences|February 18, 2017
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Hartmut Döhner, Hervé Dombret, et al.
Pageof 32

Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
Anesthesia and Analgesia|April 3, 2012
Multiple reservoirs contribute to intraoperative bacterial transmissionRandy W Loftus, Jeremiah R Brown, Matthew D Koff, et al.
Leukemia|October 3, 2018
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Anna Dolnik, Lin Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating AgentsValeria Santini, Antonio Almeida, Aristoteles Giagounidis, et al.
Journal of Hematology & Oncology|August 29, 2021
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialFarhad Ravandi, Gail J Roboz, Andrew H Wei, et al.
BMC Cancer|December 16, 2017
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimensJohn F Seymour, Hartmut Döhner, Aleksandra Butrym, et al.
Haematologica|September 23, 2021
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trialGail J Roboz, Hartmut Döhner, Christopher Pocock, et al.
Blood|October 14, 2010
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidineRaphael Itzykson, Sylvain Thépot, Bruno Quesnel, et al.
Blood|May 20, 2015
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsHervé Dombret, John F Seymour, Aleksandra Butrym, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysisJohn Koreth, Joseph Pidala, Waleska S Perez, et al.
International Journal of Molecular Sciences|February 18, 2017
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study GroupLisa Pleyer, Hartmut Döhner, Hervé Dombret, et al.
Pageof 32